You are here

AKUT MİYOKARD İNFARKTÜSÜNDE L-KARNİTİN TEDAVİSİNİN VENTRİKÜLER GEÇ POTANSİYELLER ÜZERİNE ETKİSİ

The effects of L-carnitine administriation on ventricular late potentials in patients with acute myocardial infarction

Journal Name:

Publication Year:

Abstract (2. Language): 
In this study we aimed to investigate the effects of L-carnitine administriation on ventricular late potentials in patients with acute myocardial infarction. A total of 54 patients with the diagnosis ofacut myocardial infarction were included in the study. Patients were randomly divided into two groups, L-carnitine group 27 patients (17 male, 10 female, mean age: 60+11 years), placebo group 27 patients (15 male, 12 female, mean age: 58 ±12 years). Signal averaged electrocardiogram (SOECG) recording was obtained in the first 48 hours of myocardial infarction. Measurments were repeated at the end of thrid week. L-carnitine (4gr/ day) and placebo were given to the patients randomly. Also, asetil salisilic acide, heparine infusion and if not contraindicated thrombolytic agents were given to all patients. There were no differences between two groups in the first recordings. In the second recordings while QRS duration and LAS 40 were decreased in L-carnitine group (p<0.05), it was not changed in placebo group (p>0.05). Late potential positivity was detected in 13 patients in L-carnitine group and 14 patients in placebo group in the first recordings (p>0.05). However, in the second recordings we found late potential positivity in 8 patients in L-carnitine group (p<0.05) and 12 patients in placebo group (p>0.05). It is concluded that the use of L-carnitine after acute myocardial infarction has a good effect on SOECG parameters without changing hemodynamic parameters.
Abstract (Original Language): 
Bu çalışmada akut miyokard infarktüslü olgularda L-kamitinin kullanımının, ventriküler geç potansiyeller üzerine olan etkisi araştırıldı. Çalışmaya akut miyokard infarktüsü tanısı ile kabul edilen 54 hasta alındı. Hastalar randomize olarak L-karnitin grubu 27 hasta (17 erkek, 10 kadın, yaş ort: 60±11 yıl) ve plasebo grubu 27 hasta (15 erkek, 12 kadın, yaş ort: 58±12 yıl) olarak iki gruba ayrıldı. Miyokard infarktüsünün ilk 48 saat içerisinde sinyal ortalama// elektrokardiyogrfı (SOEKG) kayıtları alındı. Ölçümler 3. hafta sonunda tekrar edildi. Hastalara randomize olarak, L-karnitin (n=27) 4x1 tb (4 gr/gün) ve plasebo verildi. Ayrıca hastaların tamamına asetil salisilik asit, heparin infüzyonu ve kontrendikasyonu olmayan vakalara trombolitik tedavi uygulandı. Birinci kayıtlarda iki grup arasında fark izlenmedi. İkinci kayıtlarda, L-karnitin grubunda QRS süresi ve LAS 40 değerlerinde düşüş izlenirken (p<0.05), plasebo grubunda ise anlamlı değişiklik olmadı (p>0.05). Geç potansiyel pozitifliği L-karnitin grubunda birinci kayıtta 13 hastada pozitif bulunurken, plasebo grubunda ise 14 hastada pozitif bulundu (p>0.05). İkinci kayıtlarda L-karnitin grubunda 8 hastada (p<0.05), plasebo grubunda 12 hastada pozitif olarak bulundu (p>0.05). Akut miyokard infaktüsünde L-karnitin kullanımının, hemodinamik veriler üzerine olumsuz bir etkisi olmadan, SOEKG parametreleri üzerine olumlu etkileri olduğu sonucuna varılmıştır.
224-228

REFERENCES

References: 

1. Schlant RC, Alexander RW (eds), O'Rourke RA, Roberts R, Sonnenblick EH. Hurst's The Heart. Eighth edition. 1994;1:893-95.
2. Pallandi RT, Perry MA, Campbell TJ. Proarrhythmic effects of an oxygen derived free radical generating system on action potentials recorded from guine pig ventricular myocardium: A possible cause of reperfusion-induced arrhytmias. Circ Res 1987;61:50-54
3. Sunamori M, Nakagawa T, Fujisawa S, Suzuk A. Myocardial response to pretreatment with L-CarnitJne in patients with cardiac replacement. Vase Surg 1991; 25:607.
4. Breidthardt G, Cain ME, El-Sherif N, Flowers NC, Hombach V, Jonse M, et al: Standart for analysis of ventricular late potentials using high-resolution or signal-averaged electrocardiography. J Am Col Cardiol 1991;17:999-1006.
5. Gardner PI, Ursell PL, Fenoglio JJ Jr, Wit AL: Electrophysiologic and anatomic basis for fractJoned electrograms recorded from healed myocardial infarcts. Circulation 1985;72:596-611.
6. Kanovsky MS, Falcone RA, Dresden CA, et al. Identification of patients with tachycardia after myocardial infarction: Signal averaged electrocardiogram, Holter monitoring and cardiac catheterization. Circulation 1984;70:264.
7. Opie LH. Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am Heart J 1979;97:375-88.
8. Whitmer JT, Hell-Wenger JA, Rovetto MJ, Neely JR. Control of fatty acid metabolism in ischemic and hypoxic hearts. J Biol Chem 1978;253:4305-9.
9. Yamada KA, McHowat J, Yan GX, et al. Cellular uncoupling induced by accumulation of long-chain acylcarnitine during ischemia. Circ Res 1994;74:83-95.
10. Heathers GP, Su CM, Adames VR, Higgins AJ. Reperfusion-induced accumulation of long-chain acylcarnitJnes in previously ischemic myocardium. J Cardivasc Pharmacol 1993;22:854-62.
11. Pande SV, Blanchaer MC. Reversible inhibition of mitochondrial adenosine diphosphate phosphorylation by long chain acyl coenzyme A esters. J Biol Chem 1971;246:402-11.
12. Lamers JM, Hulsmann WD. inhibition of (Na++K+) stimulated ATPase of heart by fatty acids. J Mol Cell Cardiol 1977;9:343-6.
13. Michael AA. Carnitine and its derivatives in Cardiovascular Diseases. Progress in Cardiovascular Diseases 1997;40:265-86.
14. Rebuzzi AG, Schiavoni G, Amico CM, Montenero AS, Meo F, Manzoli U. Beneficial effects of L-carnitine in the reduction of the necrotic area in acute myocardial infarction. Drugs Exptl Clin Res 1984;10:219-23.
15. Mouchieddine S, de Leiris J. Cardioprotective effect of L-carnitJne in rats submitted to permanent left coronary artery ligation. Arch Int Physiol Biochem Biophys 1993;101:411-6.
16. Leasure JE, Kordenat K. Effect of propionyl-L-carnitJne on experimental myocardial infarction in dogs. Cardivasc Drugs Ther 1991 (suppl 1)5:85-95.
17. Hiilsmann WC, Dubelaar ML. Carnitine requirment of vascular endothelial and smooth muscle cells in imminent ischemia. Mol Cell Biochem 1992;116:125-29.
18. Folts JD, Shug AC, Koke JR, Bittar N. Protection of the ischemic dog myocardium with carnitine. Am J Cardiol 1978;41:1209-14.
19. Gang ES, Lew AS, Hang M, Wang FZ, Siebert CA, Peter T. Decreased of ventricular late potentials after succesful thrombolytic for acute myocardial infarction. N Engl J Med 1989;321:712-6.
20. Turitto G, Risa AL, Zanchi E, Prati PL. The signal averaged electrocardiogram and ventricular arrhytmias after thrombolysis for acute myocardial infarction. J Am Coll Cardiol 1990;15:1270-6.
21. Chew EN, Mortan P, Murtagh JG, Scott ME, O'Keeffe DB. Intravenous streptokinase for acute myocardial infarction reduces the occurrence of ventricular late potentials. Br Heart J 1990;64:5-8.
22. Malik M, Kulakowski P, Udemoyima U et al. Effect of thrombolytic therapy on the predictive value of signal-averaged electrocardiography after acute myocardial infarction. Am J Cardiol 1992;70:21-5.
23. Santarelli P, Lanza GA, Natale A et al. Does thrombolysis reduce the value of late potentials for risk stratification after myocardial infarction? (Abstr). J Am Coll Cardiol 1992;19:264A.
24. Kabayashi A, Suzuki Y, Kamikawa T et al. Effects of L-carnitine on ventricular arrhytmias after coronary reperfusion. Jpn Circ J 1983;47:536-42.
25. Oliver MF, Rowe MJ, Vetter N. Metabolic intervention, in Oliver MF, Juilian DG, Donald KW (eds). Effect of acute ischemia on myocardial function. BaltJmore,MD, Williams and Wilkins. 1972:354-62.
26. Suzuki Y, Kamikawa T, Kabayashi A, Yamazaki N. Protective effects of L-carnitJne on the energy metabolism in ischemic myocardium. J Mol Cell Cardiol 1979 (suupl 3) 11:29.
27. Davini P, Bigolli A, Lamonna F, Boom A. Controlled study on L-carnitJne therapeutic efficacy in post-infarction. Drugs ExptJ Clin res 1992; 18(8):355-65.

Thank you for copying data from http://www.arastirmax.com